Buparlisib hydrochloride by Adlai Nortye Biopharma for Mantle Cell Lymphoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 23, 2023
Buparlisib hydrochloride is under clinical development by Adlai Nortye Biopharma and currently in Phase II for Mantle Cell Lymphoma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Let's personalize your content